drugset / Trial / NCT00612001

Vaccine Therapy in Treating Patients With Malignant Glioma

NCT00612001 ↗

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Vaccines made from peptides and a person's dendritic cells may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with malignant glioma.

Timeline

Start
2006-05
Primary completion
2011-01
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine Vaccine — —